Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

EXPERIMENTAL CONDITION - ANNOTATIONS

The Clinical Measurement Ontology (CMO), Measurement Methods Ontology (MMO), and Experimental Condition Ontology (XCO) are currently being developed at the Rat Genome Database. For more information about these vocabularies please see Shimoyama et al. Three ontologies to define phenotype measurement data. Front Genet. 2012;3:87. Epub 2012 May 28 or contact us (http://rgd.mcw.edu/contact/index.shtml).

Term:antineoplastic agent
go back to main search page
Accession:XCO:0000435 term browser browse the term
Definition:This is any condition in which the main influencing factor is any chemical that inhibits or prevents the proliferation of neoplasms.
Synonyms:related_synonym: anticancer agent;   cancer chemotherapy agent
 xref: CHEBI:35610



show annotations for term's descendants           Sort by:
diethylstilbestrol term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Edpm1 Estrogen-dependent pituitary mass QTL 1 IDA RGD PMID:9337394 RGD:61074 NCBI chr 2:35,134,841...88,029,593 JBrowse link
Q Edpm10 Estrogen-dependent pituitary mass QTL 10 IDA RGD PMID:9337394 RGD:61074
Q Edpm11 Estrogen-dependent pituitary mass QTL 11 IDA RGD PMID:11003699 RGD:629550 NCBI chr 9:1...43,718,459 JBrowse link
Q Edpm12 Estrogen-dependent pituitary mass QTL 12 IDA RGD PMID:11003699 RGD:629550 NCBI chr  X:2,927,898...47,927,898 JBrowse link
Q Edpm2 Estrogen-dependent pituitary mass QTL 2 IDA RGD PMID:9337394 RGD:61074 NCBI chr 2:76,539,322...202,447,032 JBrowse link
Q Edpm3 Estrogen-dependent pituitary mass QTL 3 IDA RGD PMID:9337394 RGD:61074 NCBI chr 3:53,184,692...89,878,207 JBrowse link
Q Edpm5 Estrogen-dependent pituitary mass QTL 5 IDA RGD PMID:9337394 RGD:61074 NCBI chr 5:68,984,307...104,251,008 JBrowse link
Q Edpm9 Estrogen-dependent pituitary mass QTL 9 IDA RGD PMID:9337394 RGD:61074 NCBI chr 9:63,869,687...108,869,687 JBrowse link
Q Ept1 Estrogen-induced pituitary tumorigenesis QTL 1 IDA RGD PMID:15687265 RGD:1334449 NCBI chr 6:9,843,312...20,338,915 JBrowse link
Q Ept10 Estrogen-induced pituitary tumorigenesis QTL 10 IDA RGD PMID:15687265 RGD:1334449 NCBI chr 1:192,825,253...243,914,732 JBrowse link
Q Ept13 Estrogen-induced pituitary tumorigenesis QTL 13 IDA RGD PMID:15687265 RGD:1334449 NCBI chr 1:77,494,165...122,494,165 JBrowse link
Q Ept2 Estrogen-induced pituitary tumorigenesis QTL 2 IDA RGD PMID:15687265 RGD:1334449 NCBI chr 3:47,233,430...110,362,260 JBrowse link
Q Ept6 Estrogen-induced pituitary tumorigenesis QTL 6 IDA RGD PMID:15687265 RGD:1334449 NCBI chr 3:6,537,645...10,778,823 JBrowse link
Q Ept9 Estrogen-induced pituitary tumorigenesis QTL 9 IDA RGD PMID:15687265 RGD:1334449 NCBI chr10:73,453,136...96,120,911 JBrowse link
Q Esta1 Estrogen-induced thymic atrophy QTL 1 IDA RGD PMID:16688534 RGD:1579780 NCBI chr10:21,329,805...61,345,413 JBrowse link
Q Esta2 Estrogen-induced thymic atrophy QTL 2 IDA RGD PMID:16688534 RGD:1579780 NCBI chr 2:189,599,258...226,936,289 JBrowse link
Q Esta3 Estrogen-induced thymic atrophy QTL 3 IDA RGD PMID:16688534 RGD:1579780 NCBI chr 2:136,916,935...189,599,348 JBrowse link
Q Esta4 Estrogen-induced thymic atrophy QTL 4 IDA RGD PMID:18420736 RGD:2292503 NCBI chr 3:47,233,211...147,415,807 JBrowse link
Q Eutr2 Estrogen induced uterine response QTL 2 IDA RGD PMID:16284802 RGD:1559291 NCBI chr 5:34,730,116...104,251,008 JBrowse link
Q Teswt1 Testicular weight QTL 1 IDA RGD PMID:16651691 RGD:1625009 NCBI chr 7:80,221,299...94,811,326 JBrowse link
Q Teswt2 Testicular weight QTL 2 IDA RGD PMID:16651691 RGD:1625009 NCBI chr 1:197,697,768...238,755,659 JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  experimental condition 2376
    therapeutic agent 101
      antineoplastic agent 21
        5-aza-2′-deoxycytidine 0
        5-bromo-2'-deoxyuridine 0
        5-fluorouracil 0
        Allyl isothiocyanate 0
        BTB14431 0
        UNC0638 0
        afatinib 0
        bardoxolone 0
        bleomycin 0
        cisplatin + 0
        clodronic acid + 0
        curcumin 0
        cyclophosphamide 0
        diethylstilbestrol 21
        doxorubicin + 0
        emodin 0
        epigallocatechin-3-gallate 0
        everolimus 0
        floxuridine + 0
        flutamide 0
        gefitinib 0
        gingerol 0
        lapatinib 0
        luteolin 0
        megestrol 0
        nintedanib 0
        oxaliplatin 0
        paclitaxel 0
        perhexiline maleate 0
        phloretin 0
        phosphoramidon 0
        puromycin 0
        sanguinarine 0
        sorafenib 0
        spiroplatin 0
        sunitinib 0
        taurolidine 0
        troglitazone 0
        urethane 0
        vinblastine 0
Path 2
Term Annotations click to browse term
  experimental condition 2376
    chemical 712
      chemical with specified function 517
        antineoplastic agent 21
          5-aza-2′-deoxycytidine 0
          5-bromo-2'-deoxyuridine 0
          5-fluorouracil 0
          Allyl isothiocyanate 0
          BTB14431 0
          UNC0638 0
          afatinib 0
          bardoxolone 0
          bleomycin 0
          cisplatin + 0
          clodronic acid + 0
          curcumin 0
          cyclophosphamide 0
          diethylstilbestrol 21
          doxorubicin + 0
          emodin 0
          epigallocatechin-3-gallate 0
          everolimus 0
          floxuridine + 0
          flutamide 0
          gefitinib 0
          gingerol 0
          lapatinib 0
          luteolin 0
          megestrol 0
          nintedanib 0
          oxaliplatin 0
          paclitaxel 0
          perhexiline maleate 0
          phloretin 0
          phosphoramidon 0
          puromycin 0
          sanguinarine 0
          sorafenib 0
          spiroplatin 0
          sunitinib 0
          taurolidine 0
          troglitazone 0
          urethane 0
          vinblastine 0
paths to the root